Research Article

Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease

Volume: 19 Number: 3 December 1, 2016
  • Mehmet Yaman *
  • Türkan Mete
  • İsmail Özer
  • Yasemin Kaya
  • Ahmet Karataş
TR EN

Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease

Abstract

Introduction: Diabetes mellitus (DM) and chronic kidney disease (CKD) accelerate the process of atherosclerosis. To improve clinical outcomes, non-invasive imaging modalities have been proposed to measure and monitor atherosclerosis. Recently, colour M-mode-derived propagation velocity of the descending thoracic aorta [aortic velocity propagation (AVP)] has been shown to be associated with coronary and carotid atherosclerosis.

Patients and Methods: The study population included 90 patients with type 2 diabetes who had CKD (Group 1) and 40 age- and sex-matched patients with type 2 diabetes who had a normal renal function (Group 2). Carotid intima-media thickness (CIMT) and AVP were measured. Patients with known coronary heart disease or end-stage renal disease were excluded.

Results: Compared with Group 1, patients in Group 2 had significantly lower AVP (Group 1=  29.85 ± 3.95 cm/s and Group 2= 41.05 ± 3.34 cm/s, p< 0.001) and higher CIMT (Group 1= 1.06 ± 0.11 mm and Group 2= 0.78 ± 0.10 mm, p< 0.001). There were significant correlations between AVP and CIMT (r= -0.669, p< 0.001).

Conclusion: Patients with diabetes who have CKD exhibit more subclinical atherosclerosis, which is determined by more prominent AVP and CMIT, than patients with diabetes who have a normal renal function. These simple methods might improve patient selection for the prevention of primary atherosclerotic progression.

Keywords

References

  1. 1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
  2. 2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-21.
  3. 3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al, European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1.
  4. 4. Niakan E, Harati Y, Rolak LA, Comstock JP, Rokey R. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986;146:2229.
  5. 5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154.
  6. 6. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996;50:600-8.
  7. 7. Gunes Y, Tuncer M, Guntekin U, Ceylan Y, Simsek H, Sahin M, et al. The relation between the color Mmode propagation velocity of the descending aorta and coronary and carotid atherosclerosis and flow-mediated dilatation. Echocardiography 2010;27:300-5.
  8. 8. Ognibene A, Grandi G, Lorubbio M, Rapi S, Salvadori B, Terreni A, et al. KDIGO2012 Clinical Practice Guideline CKD classification rules out creatinine clearance 24 hour urine collection? Clin Biochem 2016;49:85-9.

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Research Article

Authors

Türkan Mete This is me

İsmail Özer This is me

Yasemin Kaya This is me

Ahmet Karataş This is me

Publication Date

December 1, 2016

Submission Date

December 1, 2016

Acceptance Date

-

Published in Issue

Year 2016 Volume: 19 Number: 3

APA
Yaman, M., Mete, T., Özer, İ., Kaya, Y., & Karataş, A. (2016). Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease. Koşuyolu Heart Journal, 19(3), 167-172. https://izlik.org/JA83EC82CC
AMA
1.Yaman M, Mete T, Özer İ, Kaya Y, Karataş A. Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease. Koşuyolu Heart Journal. 2016;19(3):167-172. https://izlik.org/JA83EC82CC
Chicago
Yaman, Mehmet, Türkan Mete, İsmail Özer, Yasemin Kaya, and Ahmet Karataş. 2016. “Assessment of Subclinical Atherosclerosis With Aortic Velocity Propagation in Patients With Type 2 Diabetes and Chronic Kidney Disease”. Koşuyolu Heart Journal 19 (3): 167-72. https://izlik.org/JA83EC82CC.
EndNote
Yaman M, Mete T, Özer İ, Kaya Y, Karataş A (December 1, 2016) Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease. Koşuyolu Heart Journal 19 3 167–172.
IEEE
[1]M. Yaman, T. Mete, İ. Özer, Y. Kaya, and A. Karataş, “Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease”, Koşuyolu Heart Journal, vol. 19, no. 3, pp. 167–172, Dec. 2016, [Online]. Available: https://izlik.org/JA83EC82CC
ISNAD
Yaman, Mehmet - Mete, Türkan - Özer, İsmail - Kaya, Yasemin - Karataş, Ahmet. “Assessment of Subclinical Atherosclerosis With Aortic Velocity Propagation in Patients With Type 2 Diabetes and Chronic Kidney Disease”. Koşuyolu Heart Journal 19/3 (December 1, 2016): 167-172. https://izlik.org/JA83EC82CC.
JAMA
1.Yaman M, Mete T, Özer İ, Kaya Y, Karataş A. Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease. Koşuyolu Heart Journal. 2016;19:167–172.
MLA
Yaman, Mehmet, et al. “Assessment of Subclinical Atherosclerosis With Aortic Velocity Propagation in Patients With Type 2 Diabetes and Chronic Kidney Disease”. Koşuyolu Heart Journal, vol. 19, no. 3, Dec. 2016, pp. 167-72, https://izlik.org/JA83EC82CC.
Vancouver
1.Mehmet Yaman, Türkan Mete, İsmail Özer, Yasemin Kaya, Ahmet Karataş. Assessment of Subclinical Atherosclerosis with Aortic Velocity Propagation in Patients with Type 2 Diabetes and Chronic Kidney Disease. Koşuyolu Heart Journal [Internet]. 2016 Dec. 1;19(3):167-72. Available from: https://izlik.org/JA83EC82CC